Slide 1: Glaukos: We'll Go First
GLAUKOS WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 2: Fiscal year 2025 net revenues up 32%
For fiscal year 2025, net revenues were approximately $507 million, up 32% compared to net revenues of approximately $383 million in 2024.
Slide 3: Annual Reported Net Sales
Annual Reported Net Sales (in millions) $383 $315 $294 83 $237 g995 $181 $159 $114 $72 fl 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 + 10-Yr CAGR: 22%
Slide 4: U.S. Glaucoma
U.S. Glaucoma Our record fourth quarter U.S. Glaucoma net revenues were approximately $86.4 million, representing year-over-year growth of 53% versus 4Q 2024 driven by growing contributions from iDose TR , which generated sales of approximately $45 million in the third quarter. For fiscal year
Slide 5: Dry Eye, Glaucoma, Presbyopia, Keratoconus
Dry Eye Glaucoma Presbyopia Ocular Hypertension and Open-Angle Glaucoma ———— Keratoconus
Slide 6: Product, Patient and Status
PRODUCT PATIENT Mild-to-Moderate Glaucoma with Cat stent / iStent inject / iStent inject W iStent infinite iStent infinite Glaucoma (failed on prior therapy) Glaucoma (label expansion) PRESERFLO MicroShunt Advanced-Refractory Glaucoma Ocular Hypertension - Glaucoma Ocular Hypertension - Glaucoma Ocu
Slide 7: Annual Supplement
Annual Supplement Provided annuallly in conjunction with the fourth quarter earnings call
Slide 8: Our mission is to disrupt conventional treatment paradigms
Our mission is to disrupt conventional treatment paradigms to advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide suffering from sight-threatening chronic eye diseases. We believe our platforms and product candidates have the ability to
Slide 9: Our platforms embody ambitious, big ideas
Our platforms embody ambitious, big ideas aimed at addressing large and chronically underserved eye diseases, including for glaucoma, corneal disorders, and retinal diseases. Over the years the number of disclosed pipeline programs associated with these platforms has expanded significantly to 13 e
Slide 10: Product Patient Status
PRODUCT PATIENT STATUS Milt-t-Moderate Glaucoma with Cataract Gteuome (edn prior heap) Gtavcome (bel enposion Advnced etary lucona peso Adjunct to Glaucoma Filtration Surgery FDA Approved (2012, 2018, 2020) FDA Cleared (2022) Active PMA Study / EU MDR Cert (2025) (OUS Approved / US Active IDE Study
Slide 11: iDose TR and Ocular Hypertension programs
ose TR Ocular Hypertension - Glaucoma FDA Approved (2023) r RI Ocular Hypertension - Glaucoma Phase 3b f Ocular Hypertension - Glaucoma Phase 2b/3 ° el Ocular Hypertension - Glaucoma Pre-Clinical
Slide 12: iLution Transdermal Pharmaceuticals
iLution Transdermal Pharmaceuticals Our iLution transdermal pharmaceutical platform, which consists of patented cream-based drug formulations, are designed to be applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye
Slide 13: Additional Information
Additional Information